1. Antibody-drug Conjugate/ADC Related
  2. ADC Linker

ADC Linker

Antibody-drug conjugates (ADCs) consist of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker. An appropriate linker between the antibody and the cytotoxic drug provides a specific bridge, and thus helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers maintain ADCs’ stability during the preparation and storage stages of the ADCs and during the systemic circulation period.

The ADCs currently undergoing clinical evaluation contain linkers are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, such as reduction in the cytoplasm, exposure to acidic conditions in the lysosome, or cleavage by specific proteases within the cell. Noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule, which will retain the linker and the amino acid by which it was attached to the antibody.

The selection of linker is target dependent, based on the knowledge of the internalization and degradation of the antibody-target antigen complex, and a preclinical in vitro and in vivo activity comparison of conjugates. Moreover, the choice of a linker is also influenced by which cytotoxin is used, as each molecule has different chemical constraints, and frequently the drug structure lends itself to a specific linker.

ADC Linker Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-78738
    MC-Val-Cit-PAB 99.56%
    MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.
  • HY-20336
    Mc-Val-Cit-PABC-PNP
    Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-12362
    Val-cit-PAB-OH 99.64%
    Val-cit-PAB-OH is a peptide prodrug linker.
  • HY-41189
    Fmoc-Val-Cit-PAB-PNP
    Fmoc-Val-Cit-PAB-PNP is a peptide prodrug linker, is a linker for antibody-drug-conjugation (ADC).
  • HY-21210
    6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)-
    6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)- is an useful linker for antibody-drug-conjugations (ADCs), extracted from [Bioorg Chem. 2012 Apr-Jun;41-42:1-5.] compound 1i.
  • HY-112899
    DC1
    DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer.
  • HY-112898
    DC1-SMe
    DC1-Sme is an antibody conjugate of phosphate prodrug of cytotoxic DNA alkylators for the targeted treatment of cancer.
  • HY-111434
    UAA crosslinker 1
    UAA crosslinker 1 act as substrates for pylRS/tRNA pair that enable its incorporation into a target protein.
  • HY-78961
    6-Maleimidohexanoic acid N-hydroxysuccinimide ester 99.96%
    6-Maleimidohexanoic acid N-hydroxysuccinimide ester(ECMS) is a useful protective group in antibody drug conjugates.
  • HY-19318
    Fmoc-Val-Cit-PAB
    Fmoc-Val-Cit-PAB is a linker for antibody-drug-conjugation (ADC).
  • HY-20560
    (Ac)Phe-Lys(Alloc)-PABC-PNP
    (Ac)Phe-Lys(Alloc)-PABC-PNP is a useful chemical linker in antibody drug conjugates.